Vivan Therapeutics clears Abu Dhabi study launch for TuMatch cancer software

Vivan Therapeutics has won regulatory approval to start a clinical registration study of its TuMatch AI decision-support software at Burjeel Cancer Institute in Abu Dhabi. The colorectal cancer study will generate local outcomes and health-economics data that could shape reimbursement and wider adoption of AI tools in the UAE.

Why it matters: - The study could produce the first UAE outcomes and health-economics evidence for TuMatch, a step that matters for reimbursement and broader use across the health system. - Regulators in Abu Dhabi have cleared one of the first studies of this type of oncology software in the Emirate. - The result could help determine how AI-enabled decision support is adopted for advanced colorectal cancer care in the UAE.

What happened: - Vivan Therapeutics said it received all regulatory approvals to begin its clinical registration study of TuMatch at Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi. - The prospective study will test TuMatch in patients with colorectal cancer. - Prof. Humaid Al Shamsi will lead the study at Burjeel Cancer Institute. - The Abu Dhabi site will enroll at least 10 patients.

The details: - TuMatch is Vivan Therapeutics’ clinical decision support software for oncologists treating patients with advanced solid tumours. - The software analyzes a patient’s tumor genomic profile against Vivan’s proprietary drug-response dataset and published clinical evidence. - Vivan built the drug-response dataset using an in vivo Drosophila “avatar” screening platform developed with Mount Sinai Medical Center. - TuMatch returns a ranked set of therapeutic options for the treating oncologist. - The tool is aimed at patients who have exhausted standard-of-care regimens or are unlikely to benefit from them. - The study will collect clinical outcomes, health economics data, and value-based care data. - That evidence is intended to support reimbursement discussions with payers and inform adoption across the UAE health system. - Vivan said the study is part of its broader clinical program, which includes a planned multicentre study in pancreatic and other GI cancers at sites in Europe and the GCC. - Data from those studies are intended to support Vivan’s CE mark and FDA submissions for TuMatch. - Vivan is part of Hub71, Abu Dhabi’s global tech ecosystem. - Vivan established its regional entity in Abu Dhabi Global Market in 2025 and operates across the UK, USA, UAE and China. - The company is based at White City Place in West London.

Between the lines: - The approval gives Vivan a live clinical setting to move TuMatch beyond validation and into day-to-day treatment decisions. - Abu Dhabi is positioning itself as a hub for clinical adoption of AI-driven healthcare tools, not just development. - The focus on reimbursement evidence suggests Vivan is trying to solve both clinical utility and payer acceptance at the same time. - Colorectal cancer remains a major need case in the UAE, where patients often present younger or at later stages than in Western populations.

What’s next: - The Burjeel study will begin enrolling patients now that approvals are in place. - Vivan will use the Abu Dhabi data to support regulatory and reimbursement pathways beyond the UAE. - The company’s next clinical step includes the planned multicentre GI cancer study in Europe and the GCC. - Vivan also plans to use generated evidence to advance TuMatch toward CE mark and FDA filings.

The bottom line: - Vivan Therapeutics is turning TuMatch into a real-world clinical tool in Abu Dhabi, with the study designed to prove both patient value and economic value.